Silence Therapeutics plc XRP2.F Stock
Silence Therapeutics plc Price Chart
Silence Therapeutics plc XRP2.F Financial and Trading Overview
Silence Therapeutics plc stock price | 20.2 EUR |
Previous Close | 5.25 EUR |
Open | 5.3 EUR |
Bid | 5.3 EUR x N/A |
Ask | 5.8 EUR x N/A |
Day's Range | 5.3 - 5.3 EUR |
52 Week Range | 3.98 - 16 EUR |
Volume | 52 EUR |
Avg. Volume | 18 EUR |
Market Cap | 190.56M EUR |
Beta (5Y Monthly) | 0.739571 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.36 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2348.61 EUR |
XRP2.F Valuation Measures
Enterprise Value | 128.43M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 8.230509 |
Price/Book (mrq) | 11.496747 |
Enterprise Value/Revenue | 5.547 |
Enterprise Value/EBITDA | -2.514 |
Trading Information
Silence Therapeutics plc Stock Price History
Beta (5Y Monthly) | 0.739571 |
52-Week Change | -32.051% |
S&P500 52-Week Change | 20.43% |
52 Week High | 16 EUR |
52 Week Low | 3.98 EUR |
50-Day Moving Average | 5.4 EUR |
200-Day Moving Average | 10.09 EUR |
XRP2.F Share Statistics
Avg. Volume (3 month) | 18 EUR |
Avg. Daily Volume (10-Days) | 5 EUR |
Shares Outstanding | 35.95M |
Float | 12.44M |
Short Ratio | N/A |
% Held by Insiders | 31.87% |
% Held by Institutions | 52.99% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -185.75% |
Operating Margin (ttm) | -222.088% |
Gross Margin | 43.25% |
EBITDA Margin | -220.65% |
Management Effectiveness
Return on Assets (ttm) | -35.48% |
Return on Equity (ttm) | -417.96% |
Income Statement
Revenue (ttm) | 23.15M EUR |
Revenue Per Share (ttm) | 0.69 EUR |
Quarterly Revenue Growth (yoy) | 98.79% |
Gross Profit (ttm) | 6.62M EUR |
EBITDA | -51089000 EUR |
Net Income Avi to Common (ttm) | -43009000 EUR |
Diluted EPS (ttm) | -1.55 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 62.87M EUR |
Total Cash Per Share (mrq) | 1.75 EUR |
Total Debt (mrq) | 398K EUR |
Total Debt/Equity (mrq) | 2.4 EUR |
Current Ratio (mrq) | 4.711 |
Book Value Per Share (mrq) | 0.461 |
Cash Flow Statement
Operating Cash Flow (ttm) | -38736000 EUR |
Levered Free Cash Flow (ttm) | -22056376 EUR |
Profile of Silence Therapeutics plc
Country | Germany |
State | N/A |
City | London |
Address | 72 Hammersmith Road |
ZIP | W14 8TH |
Phone | 44 20 3457 6900 |
Website | https://www.silence-therapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 122 |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Q&A For Silence Therapeutics plc Stock
What is a current XRP2.F stock price?
Silence Therapeutics plc XRP2.F stock price today per share is 20.2 EUR.
How to purchase Silence Therapeutics plc stock?
You can buy XRP2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Silence Therapeutics plc?
The stock symbol or ticker of Silence Therapeutics plc is XRP2.F.
Which industry does the Silence Therapeutics plc company belong to?
The Silence Therapeutics plc industry is Biotechnology.
How many shares does Silence Therapeutics plc have in circulation?
The max supply of Silence Therapeutics plc shares is 46.66M.
What is Silence Therapeutics plc Price to Earnings Ratio (PE Ratio)?
Silence Therapeutics plc PE Ratio is now.
What was Silence Therapeutics plc earnings per share over the trailing 12 months (TTM)?
Silence Therapeutics plc EPS is -1.36 EUR over the trailing 12 months.
Which sector does the Silence Therapeutics plc company belong to?
The Silence Therapeutics plc sector is Healthcare.